KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Receivables (2016 - 2025)

Inovio Pharmaceuticals' Change in Receivables history spans 16 years, with the latest figure at $138278.0 for Q3 2025.

  • For Q3 2025, Change in Receivables rose 55.24% year-over-year to $138278.0; the TTM value through Sep 2025 reached -$884149.0, down 214.13%, while the annual FY2024 figure was -$1.2 million, 87.08% up from the prior year.
  • Change in Receivables for Q3 2025 was $138278.0 at Inovio Pharmaceuticals, up from -$469925.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $3.9 million in Q2 2022 and bottomed at -$8.8 million in Q1 2021.
  • The 5-year median for Change in Receivables is $81120.0 (2023), against an average of -$951850.5.
  • The largest YoY upside for Change in Receivables was 544.93% in 2021 against a maximum downside of 35616.86% in 2021.
  • A 5-year view of Change in Receivables shows it stood at $906955.0 in 2021, then surged by 82.76% to $1.7 million in 2022, then tumbled by 84.25% to $261033.0 in 2023, then tumbled by 354.25% to -$663683.0 in 2024, then skyrocketed by 120.83% to $138278.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Change in Receivables are $138278.0 (Q3 2025), -$469925.0 (Q2 2025), and $111181.0 (Q1 2025).